Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | VNN1 | O95497 | 2/20 | 0.41 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 6/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30201413 | 0.90 | HPGD (0.45) | HPGDVNN1MGLLSMN1; SMN2 | |
| SCHEMBL30202213 | 0.90 | HPGD (0.42) | HPGDVNN1GLRA1MGLLSMN1; SMN2 | |
| SCHEMBL31038243 | 0.87 | HPGD (0.49) | HPGDVNN1MGLLSMN1; SMN2 | |
| SCHEMBL29257202 | 0.86 | HPGD (0.55) | HPGDVNN1GLRA1MGLL | |
| SCHEMBL24942867 | 0.86 | HPGD (0.55) | HPGDVNN1GLRA1MGLL | |
| SCHEMBL30201417 | 0.85 | HPGD (0.40) | HPGDVNN1GLRA1MGLLSMN1; SMN2 | |
| SCHEMBL31038248 | 0.85 | HPGD (0.40) | HPGDVNN1GLRA1MGLLSMN1; SMN2 | |
| SCHEMBL30201361 | 0.85 | HPGD (0.44) | HPGDVNN1GLRA1MGLLDGAT1 | |
| SCHEMBL23680681 | 0.83 | HPGD (0.64) | HPGDMGLLGRM2 | |
| SCHEMBL23680795 | 0.82 | HPGD (0.51) | HPGDVNN1MGLLSMN1; SMN2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240294519-A1 | PYRROLO[2,3-b]PYRIDINE PGDH INHIBITORS AND METHODS OF MAKING AND USING | EPIRIUM BIO INC. | 2024-09-05 | — | — | US | disclosed |
| CN-118338902-A | Pyrrolo [2,3-b ] pyridine PGDH inhibitors and methods of making and using the same | 埃皮里姆生物股份有限公司 | 2024-07-12 | — | — | CN | disclosed |
| EP-4376841-A1 | PYRROLO[2,3-B]PYRIDINE PGDH INHIBITORS AND METHODS OF MAKING AND USING | Epirium Bio Inc. (US) | 2024-06-05 | — | — | EP | disclosed |
| WO-2023009642-A1 | PYRROLO[2,3-B]PYRIDINE PGDH INHIBITORS AND METHODS OF MAKING AND USING | EPIRIUM BIO INC. (US) | 2023-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240294519-A1 | PYRROLO[2,3-b]PYRIDINE PGDH INHIBITORS AND METHODS OF MAKING AND USING | HPGD, HPGDS, PTGIS | HPGD 1/4885VNN1 596/4885GLRA1 1422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.